Senior management team appointments at Viking Therapeutics
Viking Therapeutics Inc. made two key executive promotions as the company named Greg Zante as chief financial officer and Marianne Mancini as chief operating officer.
This author has not written his bio yet.
But we are proud to say that Andrew Humphreys contributed 3897 entries already.
Viking Therapeutics Inc. made two key executive promotions as the company named Greg Zante as chief financial officer and Marianne Mancini as chief operating officer.
Dr. Richard Woodman was appointed chief clinical officer of the Oncology Business Group of Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd.
W. Michael Flanagan, Ph.D., became chief technical officer for Avidity Biosciences Inc., a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called antibody oligonucleotide conjugates (AOCs).
Andi Weiss, director of behavioral services for MicroMass Communications, discusses how behavioral science can be used to impact current health behaviors even more effectively during the COVID-19 pandemic.
Even this far into the COVID-19 pandemic, wearing masks is still a hot-button issue in various areas across the country, according to a study by Embee Mobile and the University of California Berkeley.
Under the name FCB Health &Robin, &Robin was selected as the Nordic Partner of FCB Health Europe and immediately began servicing the Nordic region for FCB Health’s global clients.
The U.S. Food and Drug Administration approved G1 Therapeutics’ Cosela (trilaciclib) for injection to decrease the damage to the immune system and bone marrow from chemotherapy.
The World Health Organization listed AstraZeneca’s Covid-19 vaccine for emergency use, widening access in the developing world, while sources said the EU is in talks with Moderna on buying more vaccines.
Merck presented new data from the Phase III CLEAR trial (KEYNOTE-581/Study 307) at the virtual 2021 Genitourinary Cancers Symposium of the company’s checkpoint inhibitor Keytruda (pembrolizumab) and Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) in renal cell carcinoma.
The World Health Organization (WHO) on Feb. 15 listed AstraZeneca and Oxford University’s Covid-19 vaccine for emergency use, widening access to the relatively inexpensive shot in the developing world.